Rubicon Research share price
NSE: RUBICONBSE: 544578Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,436.60.
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹23,578 Cr429th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 81.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 18.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 14 Aug 2026
- 22.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 25.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,83,96969.2% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹534 Crup 3.97%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹85 Crup 10.41%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 15.9%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Jun 2025Filed 13 Nov | Sep 2025Filed 13 Nov | Dec 2025Filed 3 Feb | Mar 2026Filed 29 May | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|
| Revenue | 352 | 412 | 476 | 514 | 534 |
| Net profit | 43 | 54 | 73 | 77 | 85 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 12.3% | 13.1% | 15.3% | 14.9% | 15.9% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 100% of 247 trading days over the last year.
Mutual funds holding it
87 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 8 of the 24 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 38
- AddedAdded. Funds that held more shares than at the end of the month before.
- 18
- CutCut. Funds that held fewer shares than at the end of the month before.
- 6
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 25
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 1
| Fund | |||
|---|---|---|---|
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 37,78,406 | 0.92% | ₹611.9 Cr |
 Motilal Oswal Small Cap FundMotilal Oswal Mutual Fund | 19,65,569 | 3.84% | ₹318.3 Cr |
 HDFC Balanced Advantage FundHDFC Mutual Fund | 17,77,052 | 0.28% | ₹287.8 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 16,56,624 | 0.88% | ₹268.3 Cr |
 SBI Multicap FundSBI Mutual Fund | 16,48,216 | 1.14% | ₹266.9 Cr |
| HDFC Flexi Cap FundHDFC Mutual Fund | 13,44,729 | 0.20% | ₹217.8 Cr |
 ICICI Prudential Flexi Cap FundICICI Prudential Mutual Fund | 12,20,104 | 0.79% | ₹197.6 Cr |
 Axis ELSS Tax Saver FundAxis Mutual Fund | 9,04,407 | 0.48% | ₹146.5 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 8,76,312 | 1.66% | ₹141.9 Cr |
| Kotak Manufacture in India FundKotak Mahindra Mutual Fund | 8,33,029 | 4.31% | ₹134.9 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Rubicon Research in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 WockhardtWOCKPHARMA | 29,276 | 71.6 | 5.9 | 40.4 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Acutaas ChemicalsACUTAAS | 25,689 | 66.5 | 15.5 | 47.0 | +40.9% | +104.3% | 26.1% | 29.1% | 0.08% |
 Piramal PharmaPPLPHARMA | 25,438 | – | 3.1 | 29.4 | +0.8% | −419.8% | −3.9% | 1.1% | 0.00% |
 Neuland LaboratoriesNEULANDLAB | 24,204 | 48.6 | 12.9 | 31.5 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Granules IndiaGRANULES | 21,679 | 32.7 | – | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.22% |
 Cohance LifesciencesCOHANCE | 17,211 | 162.0 | 4.4 | 54.8 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Shilpa MedicareSHILPAMED | 16,904 | 56.9 | 6.5 | 36.6 | +27.9% | +167.6% | 12.0% | 10.9% | 0.07% |
 Caplin Point LaboratoriesCAPLIPOINT | 16,890 | 25.4 | 4.7 | 20.4 | +15.0% | +17.7% | 20.7% | 19.8% | 0.36% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 7 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
8 Oct · Updates
Aug 2026
19 Aug · Updates
Rubicon Research share price by year
Each calendar year to 2025.Rubicon Research share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 680.75 | – | 742.10 | 577.25 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,435.90 | 1,436.00 | 1,390.50 | 1,424.40 | 1,414.36 | 3,83,969 | 69.2% |
| 22 Oct 2026 | 1,448.50 | 1,451.10 | 1,393.00 | 1,436.60 | 1,421.71 | 1,60,273 | 51.0% |
| 21 Oct 2026 | 1,486.70 | 1,496.70 | 1,415.80 | 1,448.50 | 1,437.09 | 3,55,437 | 70.1% |
| 19 Oct 2026 | 1,510.80 | 1,514.80 | 1,465.50 | 1,486.70 | 1,485.47 | 1,09,636 | 54.8% |
| 16 Oct 2026 | 1,477.10 | 1,544.90 | 1,468.00 | 1,508.60 | 1,515.09 | 2,12,955 | 53.5% |
| 15 Oct 2026 | 1,517.50 | 1,517.50 | 1,450.50 | 1,477.10 | 1,471.52 | 3,33,405 | 60.7% |
| 14 Oct 2026 | 1,513.90 | 1,536.00 | 1,483.40 | 1,524.70 | 1,520.69 | 1,27,836 | 56.2% |
| 13 Oct 2026 | 1,540.20 | 1,549.80 | 1,500.00 | 1,523.40 | 1,514.09 | 1,98,616 | 54.9% |
| 12 Oct 2026 | 1,557.60 | 1,569.50 | 1,523.90 | 1,540.20 | 1,546.96 | 1,20,700 | 50.9% |
| 9 Oct 2026 | 1,535.40 | 1,559.40 | 1,503.50 | 1,548.50 | 1,529.14 | 1,47,742 | 41.6% |
About Rubicon Research
Rubicon Research is a specialty pharmaceutical company that develops and sells medicines, with a focus on regulated markets, particularly the United States. Its portfolio includes oral solids, liquids, nasal, ophthalmic, injectable and topical formulations, as well as drug-device combinations. In the United States it owns Validus Pharmaceuticals, a New Jersey-based marketer of brand-name products that specialises in CNS (central nervous system) and CVS (cardiovascular) therapies.
Research and development runs from two centres, one in Thane, Maharashtra, and one in Ontario, Canada, which works on nasal and inhalation products. A logistics and distribution unit in East Brunswick, New Jersey, is licensed to distribute prescription pharmaceuticals across 45 US states. A subsidiary, Rubicon Consumer Healthcare, develops self-care products for the Indian market.
Manufacturing sites are at Ambernath and Satara in Maharashtra, at Pithampur, Indore, in Madhya Pradesh, and at East Brunswick in New Jersey. The Satara site makes oral liquids.
Rubicon was founded in 1999 as an independent product development company. Its acquisitions include Impopharma Canada Limited, which added nasal and pulmonary drug development, Validus Pharmaceuticals, the logistics company AimRx 3PL, the Pithampur plant from Alkem Laboratories in June 2025, and an 85% stake in Arinna Lifesciences, an India based company, in April 2026. It listed on BSE and NSE in October 2025. Pratibha Pilgaonkar, the Managing Director, is a promoter. A promoter is the person or group that set up a company or controls it. Parag Sancheti is Executive Director and CEO.
- Legal name
- Rubicon Research Limited
- NSE symbol
- RUBICON
- BSE code
- 544578
- ISIN
- INE506V01022
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 2025
- Face value
- ₹1
- CIN
- U73100MH1999PLC119744
- Corporate identity number, the registrar of companies' code for it